Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 study of surovatamig (AZD0486) in relapsed or refractory B-cell acute lymphoblastic leukemia
2023-505840-20-00Phase 2Authorised
- Sponsor
- AstraZeneca
- Start
- Aug 2024
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 13
01
Overview
Phase 2, open-label trial of surovatamig in B cell acute lymphoblastic leukemia (B-ALL) (4 arms), sponsored by AstraZeneca. Primary endpoints: Frequency of dose-limiting toxicities, Safety evaluation of AZD0486 and 2 more. Planned start Aug 2024; status: authorised.
02
Drugs
surovatamig
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on 2023-505840-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505840-20-00.